Citations

Mayo Clinic

Showing 10 of 108602 citations.

Tokyo Guidelines 2018: initial management of acute biliary infection and flowchart for acute cholangitis
Miura, Fumihiko, Okamoto, Kohji , Takada, Tadahiro , Strasberg, Steven M. , Asbun, Horacio J. , Pitt, Henry A. , Gomi, Harumi , Solomkin, Joseph S. , Schlossberg, David, Kim, Myung‐Hwan , Hwang, Tsann‐Long , Chen, Miin‐Fu , Huang, Wayne Shih‐Wei, Kiriyama, Seiki , Itoi, Takao , Garden, O. James , Liau, Kui‐Hin, Liu, Keng‐Hao, Su, Cheng‐Hsi, Gouma, Dirk J., Belli, Giulio, Dervenis, Christos, Jagannath, P., Chan, Angus C. W., Lau, Wan Yee , Endo, Itaru , Santibáñes, Eduardo de , Giménez, Mariano , Jonas, Eduard , Singh, Harjit , Asai, Koji , Mori, Yasuhisa , Wada, Keita, Higuchi, Ryota , Rikiyama, Toshiki, Kano, Nobuyasu, Umezawa, Akiko , Tokumura, Hiromi, Hata, Jiro , Kozaka, Kazuto , Iwashita, Yukio , Hibi, Taizo , Yokoe, Masamichi, Kimura, Taizo, Kitano, Seigo, Inomata, Masafumi , Sumiyama, Yoshinobu, Inui, Kazuo, Yamamoto, Masakazu , Han, Ho-Seong , Horiguchi, Akihiko , Suzuki, Kenji S. , Yoon, Yoo-Seok , Honda, Goro , Watanabe, Manabu , Sata, Naohiro , Mukai, Shuntaro , Hirata, Koichi , Jonas, Eduard

Journal of Hepato-Biliary-Pancreatic Sciences | September 23, 2017 | Volume: 25 | Issue: 1 | Pages: 31-40

10.1002/jhbp.509 | PMID 28941329 Get It

AbstractThe initial management of patients with suspected acute biliary infection starts with the measurement of vital signs to assess whether or not the situation is urgent. If the case is judged to be urgent, initial medical treatment should be started immediately including respiratory/circulatory management if required, without waiting for a definitive diagnosis. The patient's medical history is then taken; an abdominal examination is performed; blood tests, urinalysis, and diagnostic imaging are carried out; and a diagnosis is made using the diagnostic criteria for cholangitis/cholecystitis. Once the diagnosis has been confirmed, initial medical treatment should be started immediately, severity should be assessed according to the severity grading criteria for acute cholangitis/cholecystitis, and the patient's general status should be evaluated. For mild acute cholangitis, in most cases initial treatment including antibiotics is sufficient, and most patients do not require biliary drainage. However, biliary drainage should be considered if a patient does not respond to initial treatment. For moderate acute cholangitis, early endoscopic or percutaneous transhepatic biliary drainage is indicated. If the underlying etiology requires treatment, this should be provided after the patient's general condition has improved; endoscopic sphincterotomy and subsequent choledocholithotomy may be performed together with biliary drainage. For severe acute cholangitis, appropriate respiratory/circulatory management is required. Biliary drainage should be performed as soon as possible after the patient's general condition has been improved by initial treatment and respiratory/circulatory management. Free full articles and mobile app of TG18 are available at: http://www.jshbps.jp/modules/en/index.php?content_id=47. Related clinical questions and references are also included.
Hospital costs for patients with lower extremity cellulitis: a retrospective population-based study
Challener, Douglas W. , Marcelin, Jasmine R , Visscher, Sue L. , Baddour, Larry M. , Challener, Douglas , Marcelin, Jasmine , Visscher, Sue, Baddour, Larry

Hospital Practice | September 23, 2017 | Volume: 45 | Issue: 5 | Pages: 196-200

10.1080/21548331.2017.1384690 | PMID 28944703 Get It

Nonalcoholic fatty liver disease incidence and impact on metabolic burden and death: A 20 year‐community study
Therneau, Terry M. , Larson, Joseph J. , Coward, Alexandra, Kamath, Patrick S. , Allen, Alina M. , Somers, Virend K.

Hepatology | September 23, 2017 | Volume: 67 | Issue: 5 | Pages: 1726-1736

10.1002/hep.29546 | PMID 28941364 Get It

Recent population‐based data on nonalcoholic fatty liver disease (NAFLD) epidemiology in general, and incidence in particular, are lacking. We examined trends in NAFLD incidence in a U.S. community and the impact of NAFLD on incident metabolic comorbidities (MCs), cardiovascular (CV) events, and mortality. A community cohort of all adults diagnosed with NAFLD in Olmsted County, Minnesota, between 1997 and 2014 was constructed using the Rochester Epidemiology Project database. The yearly incidence rate were calculated. The impact of NAFLD on incident MCs, CV events, and mortality was studied using a multistate model, with a 4:1 age‐ and sex‐matched general population as a reference. We identified 3,869 NAFLD subjects (median age, 53; 52% women) and 15,209 controls; median follow‐up was 7 (1‐20) years. NAFLD incidence increased 5‐fold, from 62 to 329 in 100,000 person‐years. The increase was highest (7‐fold) in young adults, aged 18‐39 years. The 10‐year mortality was higher in NAFLD subjects (10.2%) than controls (7.6%; P < 0.0001). NAFLD was an independent risk factor for incident MCs and death. Mortality risk decreased as the number of incident MCs increased: relative risk (RR) = 2.16 (95% confidence [CI], 1.41‐3.31), 1.99 (95% CI, 1.48‐2.66), 1.75 (95% CI, 1.42‐2.14), and 1.08 (95% CI, 0.89‐1.30) when 0, 1, 2, or 3 MCs were present, respectively. The NAFLD impact on CV events was significant only in subjects without MCs (RR = 1.96; 95% CI = 1.35‐2.86). NAFLD reduced life expectancy by 4 years, with more time spent in high metabolic burden. Conclusion: Incidence of NAFLD diagnosis in the community has increased 5‐fold, particularly in young adults. NAFLD is a consequence, but also a precursor of MC. Incident MC attenuates the impact of NAFLD on death and annuls its impact on CV disease. (H epatology 2018;67:1726‐1736).
Utilization of Leads After Permanent Implant in Spinal Cord Stimulator Systems
Sanders, Rebecca A., Hoelzer, Bryan C. , Bendel, Markus A. , Lamer, Tim J. , Eldrige, Jason S. , Pingree, Matthew J. , Moeschler, Susan M. , Gazelka, Halena M. , Mauck, William D. , Rho, Richard H., Mauck, W David, Pittelkow, Thomas P.

Pain Practice | September 23, 2017 | Volume: 18 | Issue: 5 | Pages: 562-567

10.1111/papr.12644 | PMID 28941145 Get It

AbstractObjectiveThe goal of this study was to determine the frequency and clinical indications associated with implantation of single vs. dual percutaneous lead spinal cord stimulator (SCS) systems and to look further into how these leads are utilized for treatment.Materials and MethodsA retrospective cohort analysis of all patients undergoing SCS implantation between January 2001 and December 2013 with a minimum of 2 years of clinical follow‐up was performed. Number of trial leads and implanted leads was recorded. For patients with dual‐lead systems, it was noted if and when the second lead was used, along with the clinical indication for lead activation.ResultsIn the 259‐patient cohort, 15.8% (n = 41) patients underwent placement of a single‐lead system, 83.0% (n = 215) underwent placement of a dual‐lead system, and 1.2% (n = 3) underwent placement of 3‐lead systems. Placement of dual‐lead systems was similar among all indication groups. Of those patients with a dual‐lead system in place, 88.1% utilized both leads and average time to programming of the second lead was 2.3 months. The most common reason to activate the second lead was inadequate stimulation coverage. Five of the 41 patients with single‐lead systems underwent an additional surgery to implant a second lead due to inadequate stimulation with 1 lead.ConclusionsTo our knowledge this is the first descriptive analysis of the frequency of single‐ and dual‐lead SCS systems. This report indicates that dual‐lead systems are most often placed and both leads are required for optimal patient therapy.
Comparative outcomes of transcatheter aortic valve replacement in African American and Caucasian patients with severe aortic stenosis
Aljohani, Sami, Almustafa, Ahmad, Al‐Hijji, Mohammed , Ali, Oluseun O., Holmes, David R. , Alkhouli, Mohamad , Al-Hijji, Mohammed A , Alkhouli, Mohamad , Alqahtani, Fahad

Catheterization and Cardiovascular Interventions | September 23, 2017 | Volume: 91 | Issue: 5 | Pages: 932-937

10.1002/ccd.27257 | PMID 28941139 Get It

AbstractBackgroundRacial disparities in cardiovascular care have been extensively investigated. The introduction of transcatheter aortic valve replacement (TAVR) revolutionized the treatment of aortic stenosis (AS) in the last decade. Whether a racial disparity in the utilization and outcome of TAVR exists is unknown.MethodsWe utilized the nationwide inpatient sample (NIS) to compare utilization rates, and in‐hospital outcomes of Caucasians and African American (AA) patients who underwent TAVR between August 2011 and December 2014.ResultsA total of 7,176 patients (6870 Caucasians, 95.7%) and (306 AAs, 4.3%) were included in this analysis. Among patients who underwent aortic valve replacement between 2011 and 2014, the rates of TAVR utilization increased from 0.32% to 7.6% in AAs and from 0.4% to 8.8% in Caucasians. In propensity‐matched cohorts of patients (n = 300 Caucasians and n = 300 AAs), in‐hospital mortality was similar (3.7% and 3.3%, respectively, P = 0.99). Also, rates of key complications including stroke, permanent pacemaker implantation (PPMI), vascular complications, acute kidney injury, new dialysis, blood transfusion, and tamponade were similar in both races. There was also no significant difference between Caucasians and AAs with regards to length of stay, cost of hospitalization, and intermediate care facility utilization.ConclusionsThere was no significant difference in the utilization rates, in‐hospital outcomes, and cost of TAVR between Caucasians and AA patients in contemporary US practice. Further comparative studies of surgical and TAVR in AAs and other racial minorities are warranted.
Paired comparison of therapeutic plasma exchange using the Fenwal Amicus versus TerumoBCTSpectra Optia
Burgstaler, Edwin A. , Bryant, Sandra C. , Winters, Jeffrey L. , Winters, Jeffrey L

Journal of Clinical Apheresis | September 23, 2017 | Volume: 33 | Issue: 3 | Pages: 265-273

10.1002/jca.21589 | PMID 28940323 Get It

PurposeTerumo BCT Spectra Optia (O) and Fenwal Amicus (A) can perform therapeutic plasma exchange (TPE). We compared these systems in a prospective, randomized, crossover study of 81 paired procedures. Primary objective was to determine if there was a difference in platelet loss between the instruments. Secondary objectives were to determine differences in procedure time (PT), plasma removal efficiency (PRE 1), plasma removal rate (PRR), and fluid balance (FB).MethodsFifty‐seven adults undergoing 162 procedures were included. Diagnoses included neurologic, nephrologic, and hematologic diseases. Replacement fluids included 5% normal serum albumin and/or fresh frozen plasma. The first instrument (randomized) established the inlet flow rate for the second with a maximum inlet rate of 120 ml/min. Spun HCT was used to program the procedure. One plasma volume was exchanged, for both instruments. Multivariable general estimating equations were used to assess the relationship between the outcome variables with machine after adjusting for covariates, with P values <.05 significant.ResultsMedian total blood volume (4,775 mL‐A, 4,775 mL‐O) and preprocedure spun HCT (33%‐A, 34%‐O) were not statistically different. The plasma removed (3196 mL‐A, 3120 mL‐O), PLT in waste plasma (0.62 × 1011‐A, 0.33 × 1011‐O), PLT decline (8.5%‐A, 6.5%‐O), and PRR (48.1 mL/min‐A, 49.2 mL/min‐O) were not statistically different. There were statistically significant, but clinically irrelevant, differences in PLT CE1 (6.2%‐A, 3.6%‐O), PRE 1 (85.3%‐A, 83.9%‐O), FB (+2 mL‐A,+15 mL‐O), and PT (71 min‐A, 71 min‐O).ConclusionsStatistical differences were seen but none were of a magnitude to be clinically relevant, indicating comparable TPE performance.
Feeding Tubes and Health Care Service Utilization in Amyotrophic Lateral Sclerosis: Benefits and Limits to a Retrospective, Multicenter Study Using Big Data
Sangaralingham, Lindsey R. , Shah, Nilay D. , Tilburt, Jon C. , Swetz, Keith M. , Peterson, Stephanie M, Hurt, Ryan T. , Dunlay, Shannon M. , Peterson, Stephanie M. Peck

INQUIRY: The Journal of Health Care Organization, Provision, and Financing | September 23, 2017 | Volume: 54 | Issue: No issue available | Pages: No page available

10.1177/0046958017732424 | PMID 28942701 Get It

Amyotrophic lateral sclerosis (ALS) is a progressive, fatal neurologic disorder with predictable challenges regarding disease progression and end-of-life care. These include need for respiratory and nutritional support. Little is known about how such choices impact end-of-life health service utilization for these patients. Using OptumLabs Data Warehouse, a large administrative claims database with more than 150 million privately insured, geographically diverse enrollees, we sought to explore outcomes associated with the use of enteral nutrition (EN). Patients were of age ≥18 years, with first ALS diagnosis during calendar years 2006-2012, and 6 months of continuous health plan coverage before first diagnosis. EN use was identified using procedure codes. Data were summarized descriptively. Among 1974 patients with ALS, mean age was 60.0 ± 12.5 years, 41.8% were women, and 9.7% demonstrated use of EN. Median time from ALS diagnosis to evidence of EN was 211 days (interquartile range [IQR]: 70-426). Those receiving EN had greater aggregate comorbidity (47% with Charlson-Deyo Comorbidity Index ≥ 3 vs only 27% in non-EN subset). In total, 38.1% of patients had at least 1 hospitalization, with median time to hospitalization of 162 days. Unfortunately, the EN group ended coverage a median of 155 days after EN started (IQR: 63.5-388), thereby limiting ability to capture outcomes. Although many ALS patients were identified, EN use was lower than expected, due to being earlier in disease trajectory and lost to follow-up with transition from private insurance. As such, databases exclusively including privately insured patients may be suboptimal for detecting late complications of protracted illnesses.
Deoxycholic acid promotes development of gastroesophageal reflux disease and Barrett's oesophagus by modulating integrin‐αv trafficking
Prichard, David O. , Byrne, Anne-Marie , O’Sullivan, Jacintha , Feighery, Ronan, Doyle, Brendan, Eldin, Osama Sharaf, Finn, Stephen P. , Duff, Deirdre, Kelleher, Dermot, Long, Aideen , Murphy, James Oliver , Reynolds, John V. , Maguire, Aoife A.

Journal of Cellular and Molecular Medicine | September 23, 2017 | Volume: 21 | Issue: 12 | Pages: 3612-3625

10.1111/jcmm.13271 | PMID 28941013 Get It

AbstractThe fundamental mechanisms underlying erosive oesophagitis and subsequent development of Barrett's oesophagus (BO) are poorly understood. Here, we investigated the contribution of specific components of the gastric refluxate on adhesion molecules involved in epithelial barrier maintenance. Cell line models of squamous epithelium (HET‐1A) and BO (QH) were used to examine the effects of bile acids on cell adhesion to extracellular matrix proteins (Collagen, laminin, vitronectin, fibronectin) and expression of integrin ligands (α3, α4, α5, α6 and αν). Experimental findings were validated in human explant oesophageal biopsies, a rat model of gastroesophageal reflux disease (GORD) and in patient tissue microarrays. The bile acid deoxycholic acid (DCA) specifically reduced adhesion of HET‐1A cells to vitronectin and reduced cell‐surface expression of integrin‐αν via effects on endocytic recycling processes. Increased expression of integrin‐αv was observed in ulcerated tissue in a rat model of GORD and in oesophagitis and Barrett's intestinal metaplasia patient tissue compared to normal squamous epithelium. Increased expression of integrin‐αν was observed in QH BO cells compared to HET‐1A cells. QH cells were resistant to DCA‐mediated loss of adhesion and reduction in cell‐surface expression of integrin‐αν. We demonstrated that a specific component of the gastric refluxate, DCA, affects the epithelial barrier through modulation of integrin αν expression, providing a novel mechanism for bile acid‐mediated erosion of oesophageal squamous epithelium and promotion of BO. Strategies aimed at preventing bile acid‐mediated erosion should be considered in the clinical management of patients with GORD.
PD-1 Blockade Promotes Epitope Spreading in Anticancer CD8+ T Cell Responses by Preventing Fratricidal Death of Subdominant Clones To Relieve Immunodomination
Memarnejadian, Arash , Meilleur, Courtney, Shaler, Christopher R. , Khazaie, Khashayarsha , Bennink, Jack R., Schell, Todd D. , Haeryfar, S. M. Mansour

The Journal of Immunology | September 23, 2017 | Volume: 199 | Issue: 9 | Pages: 3348-3359

10.4049/jimmunol.1700643 | PMID 28939757 Get It

Abstract The interactions between programmed death-1 (PD-1) and its ligands hamper tumor-specific CD8+ T cell (TCD8) responses, and PD-1-based “checkpoint inhibitors” have shown promise in certain cancers, thus revitalizing interest in immunotherapy. PD-1–targeted therapies reverse TCD8 exhaustion/anergy. However, whether they alter the epitope breadth of TCD8 responses remains unclear. This is an important question because subdominant TCD8 are more likely than immunodominant clones to escape tolerance mechanisms and may contribute to protective anticancer immunity. We have addressed this question in an in vivo model of TCD8 responses to well-defined epitopes of a clinically relevant oncoprotein, large T Ag. We found that unlike other coinhibitory molecules (CTLA-4, LAG-3, TIM-3), PD-1 was highly expressed by subdominant TCD8, which correlated with their propensity to favorably respond to PD-1/PD-1 ligand-1 (PD-L1)-blocking Abs. PD-1 blockade increased the size of subdominant TCD8 clones at the peak of their primary response, and it also sustained their presence, thus giving rise to an enlarged memory pool. The expanded population was fully functional as judged by IFN-γ production and MHC class I–restricted cytotoxicity. The selective increase in subdominant TCD8 clonal size was due to their enhanced survival, not proliferation. Further mechanistic studies utilizing peptide-pulsed dendritic cells, recombinant vaccinia viruses encoding full-length T Ag or epitope mingenes, and tumor cells expressing T Ag variants revealed that anti–PD-1 invigorates subdominant TCD8 responses by relieving their lysis-dependent suppression by immunodominant TCD8. To our knowledge, our work constitutes the first report that interfering with PD-1 signaling potentiates epitope spreading in tumor-specific responses, a finding with clear implications for cancer immunotherapy and vaccination.
In Reply
Dowdy, Sean C. , Lovely, Jenna K. , Bakkum‐Gamez, Jamie N.

Obstetrics & Gynecology | September 22, 2017 | Volume: 130 | Issue: 4 | Pages: 914-915

10.1097/aog.0000000000002304 | PMID 28937562 Get It